Comparison of growth features and cancer stem cell prevalence in intrahepatic and extrahepatic cholangiocarcinoma cell lines.
| Autor: | Yang J; University of Manitoba, Canada., Sontag DP; University of Manitoba, Canada., Burczynski FJ; University of Manitoba, Canada., Xi S; Xiamen University, China., Gong Y; University of Manitoba, Canada., Minuk GY; University of Manitoba, Canada. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical and experimental hepatology [Clin Exp Hepatol] 2022 Mar; Vol. 8 (1), pp. 60-69. Date of Electronic Publication: 2022 Mar 23. |
| DOI: | 10.5114/ceh.2022.114192 |
| Abstrakt: | Aim of the Study: Intra- and extrahepatic cholangiocarcinoma (I-CCA and E-CCA respectively) exhibit different growth features that contribute to different clinical outcomes. Cancer stem cells (CSCs) influence tumor growth and thereby may be responsible for these differences. The aim of this study was to document and compare the growth features of human I-CCA and E-CCA cell lines and determine whether any differences observed could be explained by differences in the prevalence and/or stem cell surface marker (SCSM) expression profiles of CSCs within the tumor cell lines. Material and Methods: Six CCA cells lines, three I-CCA and three E-CCA, were studied. Tumor cell growth features including cell proliferation, colony/spheroid formation, migration and invasion were documented. CSC prevalence and SCSM expression profiles were examined by flow cytometry. Results: I-CCA cells had significantly increased proliferative activity, shorter doubling times and were more invasive than E-CCA cells, while colony/spheroid formation and migration were similar in the two cell populations. There were no significant differences in CSC prevalence rates or SCSM expression profiles. Conclusions: These findings suggest that I-CCA cells proliferate at a more rapid rate and are more invasive than E-CCA cells but the differences cannot be explained by differences in the prevalence or SCSM expression profiles of CSCs within the tumor cell population. Competing Interests: The authors declare no conflict of interest. (Copyright © 2022 Clinical and Experimental Hepatology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|